AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
P/E ratio for AVROBIO, Inc. (AVRO)
P/E ratio as of 2023: 59.51
According to AVROBIO, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 59.51. At the end of 2022 the company had a P/E ratio of -3.53.
P/E ratio history for AVROBIO, Inc. from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 59.51 |
| 2022 | -3.53 |
| 2021 | -16.82 |
| 2020 | -51.11 |
| 2019 | -91.89 |
| 2018 | -57.90 |
| 2017 | -325.01 |
| 2016 | -555.67 |